Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wolff

Showing results (811-820 of 831) with videos related to

Pageof 84
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Breast cancer, version 3.2013: featured updates to the NCCN guidelinesRichard L Theriault, Robert W Carlson, Craig Allred, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesRachel A Freedman, Rebecca S Gelman, Carey K Anders, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 11, 2014
Breast cancer version 3.2014William J Gradishar, Benjamin O Anderson, Sarah L Blair, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research DirectionsRyan J O Dowling, Joseph A Sparano, Pamela J Goodwin, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical ConsiderationsRyan J O Dowling, Kevin Kalinsky, Daniel F Hayes, et al.
NPJ Breast Cancer|May 11, 2026
Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2)Yara Abdou, Mariya Rozenblit, Dario Trapani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2026
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual DiseaseNatasha B Hunter, Heather A Parsons, Leslie Cope, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
The Lancet. Oncology|July 17, 2025
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysisGuillermo Villacampa, Tomás Pascual, Paolo Tarantino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancerG Villacampa, N M Tung, S Pernas, et al.
Pageof 84

Showing results (811-820 of 831) with videos related to

Sort By:
Pageof 84
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Breast cancer, version 3.2013: featured updates to the NCCN guidelinesRichard L Theriault, Robert W Carlson, Craig Allred, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesRachel A Freedman, Rebecca S Gelman, Carey K Anders, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 11, 2014
Breast cancer version 3.2014William J Gradishar, Benjamin O Anderson, Sarah L Blair, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research DirectionsRyan J O Dowling, Joseph A Sparano, Pamela J Goodwin, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical ConsiderationsRyan J O Dowling, Kevin Kalinsky, Daniel F Hayes, et al.
NPJ Breast Cancer|May 11, 2026
Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2)Yara Abdou, Mariya Rozenblit, Dario Trapani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2026
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual DiseaseNatasha B Hunter, Heather A Parsons, Leslie Cope, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
The Lancet. Oncology|July 17, 2025
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysisGuillermo Villacampa, Tomás Pascual, Paolo Tarantino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancerG Villacampa, N M Tung, S Pernas, et al.
Pageof 84